FDA Clearance Tracker · K050374
ADVIA IMS LITHIUM ASSAY
Last checked: Nov 19, 2026Latest source record: Jun 15, 2005 (this decision)Source: openFDAMethods & limitations
Decided
Jun 15, 2005
Substantially Equivalent
Time to decision
121 days
Received Feb 14, 2005. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K050374
- Device name
- ADVIA IMS LITHIUM ASSAY
- Applicant
- Bayer Healthcare, LLC
- Applicant location
- Tarrytown, NY
- Received
- Feb 14, 2005
- Decided
- Jun 15, 2005
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device class
- Class II
- Regulation
- 21 CFR 862.3560
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code NDW. The earliest in FDA's data is K003583, decided Jan 17, 2001.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K050374
- The applicant filed a summary instead of a public summary, or the summary is not at FDA's usual address. Check the FDA record.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Bayer Healthcare, LLC
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K171802 · Decided Mar 7, 2018 · 261 days after receipt
Device type: Stimulator, Nerve, Transcutaneous, Over-The-Counter (NUH) · Neurology & Neurosurgery
K152852 · Decided Dec 22, 2015 · 84 days after receipt
Device type: Stimulator, Nerve, Transcutaneous, Over-The-Counter (NUH) · Neurology & Neurosurgery
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.